In this podcast, Contributing Editor Dr. Brad Kahl has a conversation with Dr. Steven Horwitz. They discuss Dr. Kahl's Diffusion article from the March/April 2019 issue of The Hematologist. The article titled, "Keeping Your ESCHELONs Straight," covers the ESCHELON-2 study, a trial that used a "repeal and replace" strategy, eliminating vincristine from the experimental regimen and substituting in brentuximab vedotin to treat CD30+ T-cell lymphoma. You can find his Diffusion article online at www.hematology.org/Thehematologist/Diffusion/9387.aspx.

Dr. Steven Horwitz conflicts of interest include: He has received grants and research support from ADCT Therapeutics, Aileron, Celgene, Forty-Seven, Infinity/Verastem, Kyowa-Hakka-Kirin, Millenium/Takeda, Seattle Genetics and Trillipum, and is a consultant for ADCT Therapeutics, Aileron, Corvus, Forty-Seven, Innate Pharma, Kyowa-Hakka, Kirin, Takeda, Miragen, Mundipharma, Portola, Seattle Genetics, Beigene, Affimed, and Verastem.

Music: "Jellyfish in Space" Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/